Advancing AAV gene therapy together: Continuing our collaboration with Mirugen
Building on the success of an initial project, Mirugen, a company developing gene-agnostic regenerative therapies for retinal diseases, has engaged DINAMIQS to support a second project involving engineered capsids.
Our team is providing process development and manufacturing support for the novel capsids, helping advance Mirugen’s gene therapy program. The continued collaboration reflects the trust established through our first project and our shared commitment to accelerating innovative therapies for patients.
Mirugen’s feedback underscores the strength of the partnership and the value of DINAMIQS’ collaborative approach:
“DINAMIQS has been a trusted manufacturing partner. The team is proactive, pragmatic, and solution oriented.” – Charlotte Casebourne Stock, Executive Chair, Mirugen
Our ongoing work with Mirugen reflects a collaboration model designed to give customers the technical support, flexibility, and transparency they need to advance complex gene therapy programs with confidence:
- Direct access to viral vector experts
- Flexible and transferable manufacturing platforms
- Strong focus on process scalability and future GMP readiness
- Transparent collaboration and technical problem-solving
- Reliable execution and responsiveness throughout the project lifecycle
As an independent viral vector CDMO and part of the Siegfried Group, DINAMIQS combines scientific expertise with a flexible manufacturing platform designed to support clients from early development through GMP manufacturing. We are committed to providing transparent, collaborative, and adaptable solutions that allow our partners to retain long-term control over their programs and manufacturing strategy.
We thank the Mirugen team for their continued trust and look forward to contributing to the successful advancement of Mirugen’s transformative medicine.